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OBJECTIVE — Aldose reductase (ALR) is involved in diabetic microvascular damage via the
polyol pathway. A recent meta-analysis found genetic variation in the ALR gene (AKR1B1)t ob e
signiﬁcantly associated with diabetic retinopathy (DR). We investigated the genetic association
of AKR1B1 with DR.
RESEARCH DESIGN AND METHODS — The study enrolled 909 individuals with
diabetes. Participants were genotyped for an AKR1B1 (CA)n microsatellite and 14 tag single
nucleotide polymorphisms, and ophthalmological assessment was performed.
RESULTS — A total of 514 individuals were found to have DR. rs9640883 was signiﬁcantly
associatedwithDR(P0.0005).However,AKR1B1variationwasnotindependentlyassociated
with DR development after adjusting for relevant clinical parameters. rs9640883 was associated
with duration of diabetes (P  0.002).
CONCLUSION — Many previous reports have failed to account for known risk factors for
DR. The commonly reported association of AKR1B1 with DR may be due to an association of the
gene with younger age at onset of diabetes.
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T
hepolyolpathwayisinvolvedinmi-
crovascular damage, a hallmark of
diabetic retinopathy (DR). Aldose
reductase (ALR) is the ﬁrst and rate-
limiting enzyme in the polyol pathway,
and pathogenic vascular and hemody-
namic changes contributing to DR can
subsequently occur as a result of sorbitol
accumulation, oxidative damage, and
protein kinase C activation (1–3). Over
160 candidate gene studies have been re-
ported for DR, and their recent meta-
analysis found genetic variation in the
ALR gene (AKR1B1) to be the most signif-
icantly associated with DR (4). We aimed
to determine whether genetic variation in
the AKR1B1 gene was associated with DR
in a large cohort of Australian patients
with type 1 or type 2 diabetes.
RESEARCH DESIGN AND
METHODS— After receiving approval
from relevant Human Research Ethics
Committees, participants diagnosed with
type 1 diabetes (n  271) or type 2 dia-
betes (n  638) with a minimum 5-year
duration were recruited from ophthal-
mology and endocrinology outpatient
clinics of three tertiary hospitals in Ad-
elaide, Australia. Retinopathy status for
theworsteyewasgradedaccordingtothe
Early Treatment Diabetic Retinopathy
Study criteria (5). If either eye had clini-
cally signiﬁcant macular edema (CSME),
irrespectiveofotherDRgradings,thepar-
ticipant was also classiﬁed as having
CSME. Blinding DR was deﬁned as severe
nonproliferative DR (NPDR), prolifera-
tive DR (PDR), or CSME.
Blood pressure, BMI, renal function
tests, serum cholesterol, and A1C levels
were obtained. Hypertension was deﬁned
as blood pressure 140/90 mmHg or use
of antihypertensive medication at recruit-
ment. Hypercholesterolemia was deﬁned
as total cholesterol of 5.5 mmol/l or use
of lipid-lowering medication. Albumin-
uria was deﬁned as urine albumin 30
mg/day.
TheAKR1B1(CA)nmicrosatellitewas
PCRampliﬁedusingﬂuorescentlylabeled
primers published by Ko et al. (6) in 883
individuals(263withtype1and620with
type 2 diabetes) and genotyped by elec-
trophoresis on an ABI PRISM 3100 (Ap-
plied Biosystems).
Using the tagger program imple-
mented in Haploview 4.0, 14 tag single
nucleotide polymorphisms (SNPs) across
theAKR1B1gene,includingthepromoter
region, were selected and genotyped in
909 individuals (271 with type 1 and 638
with type 2 diabetes) using iPLEX Gold
chemistry on an autoﬂex mass spectrom-
eter (Sequenom, San Diego, CA).
The
2testforcategoricalandunivar-
iate binary logistic regression for contin-
uous clinical covariates with DR were
calculatedinSPSS(version15.0;SPSS,Chi-
cago, IL). Allelic and genotypic associations
of the (CA)n microsatellite were calculated
using the 
2 test and multivariate anal-
ysis with the binary logistic regression
controlling for associated variables.
Testing for association of all SNPs and
haplotypes with DR was undertaken
with the 
2 test for univariate analysis
andbinarylogisticformultivariateanal-
ysis in PLINK (version 1.06) (7) and
also CLUMPHAP (8) when microsatel-
lites were incorporated into haplotype
analyses.
Bonferroni correction was applied to
microsatellite and haplotype analyses.
Multiple testing of individual SNPs was
adjusted for using Nyholt’s SNP spectral
decomposition method (9), modiﬁed by
Li and Ji (10), which estimated 10 inde-
pendent tests.
RESULTS— A total of 514 partici-
pants had DR, of which 311 had NPDR
(95 with type 1 and 216 with type 2 dia-
betes), 188 had PDR (71 with type 1 and
117 with type 2 diabetes), and 150 had
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2 diabetes).
For the AKR1B1 microsatellite, 13 al-
leles (120–144 bp) were present in our
cohort.The138bpallele(24repeats)was
designated as the z allele. The z-10/z-8
genotype was signiﬁcantly associated
with blinding DR in type 1 diabetes (P 
0.008) and remained signiﬁcant in the
multivariate analysis (P  0.001) and af-
ter correction for multiple testing (P 
0.007).However,onlytwoandsixpartic-
ipants with no DR and blinding DR re-
spectively, carried this genotype, and the
signiﬁcance of this result is unclear. No
association of the microsatellite with DR
was detected in type 2 diabetes.
rs9640883 was signiﬁcantly associ-
ated with DR in combined diabetes (P 
0.0005; odds ratio 1.62 [95% CI 1.24–
2.13]), and type 2 diabetes (P  0.002;
5.73 [4.26–7.69 ]) under the dominant
model. This remained signiﬁcant (P 
0.005) after correction for multiple test-
ing. Haplotype analyses revealed no asso-
ciations with DR. No tag SNP remained
associated with DR after adjustment for
associated covariates for type 1 (age, dia-
betes duration, hypertension, albumin-
uria, and hypercholesterolemia) and type
2 diabetes (sex, diabetes duration, hyper-
tension, and A1C (Table 1). Each SNP
was subsequently tested for association
witheachindividualcovariateinaunivar-
iate analysis. Of note, rs9640883 was as-
sociatedwithdurationofdiabetesundera
dominant model (P  0.014), particu-
larly in the type 2 diabetes cohort (P 
0.002).
CONCLUSIONS— There have been
numerous studies assessing polymor-
phisms of the AKR1B1 gene and DR sus-
ceptibility, with (CA)n microsatellite and
rs759853 most commonly studied. A re-
centmeta-analysisfoundthez2allelein
type1diabetes,andz2alleleinanytype
ofdiabetesconferredprotectionfromand
risk for DR, respectively. The C allele of
rs759853 conferred risk for DR in type 1
diabetes (4).
This study examined the (CA)n mic-
rosatellite and 14 tag SNPs. Although
AKR1B1 variation was associated with
DR, once established risk factors includ-
ing diabetes duration and A1C were con-
sidered, no association remained. This
suggests that particular SNPs may be as-
sociatedwiththeclinicalcovariatesrather
than having a direct association with DR.
We found the DR-associated SNP
rs9640883 to also be associated with du-
ration of diabetes. ALR reduces toxic al-
dehydes generated by reactive oxygen
species to inactive alcohols. Decreased
availability of the cofactor NADPH could
induce or exacerbate intracellular oxida-
tive stress (1). Chronic hyperglycemia
and oxidative stress can result in perma-
nent irreversible damage to pancreatic
-cells (11). Subsequent deterioration of
-cell function and increased disease se-
verity results, with animal studies provid-
ing support for this hypothesis (12,13).
Variation in ALR activity may affect the
extent of oxidative stress, and genetic
variation in AKR1B1 may account for al-
tered ALR activity. The association ob-
served between rs9640883 and DR, and
those previously reported for this gene,
may reﬂect the effect this gene has on age
of onset of diabetes and therefore on dia-
betes duration, in turn inﬂuencing DR
risk (14,15).
The majority of previous studies exam-
iningtherelationshipbetweenAKR1B1and
DR have not undertaken multivariate anal-
ysis to consider known risk factors for DR.
They may be inﬂuenced by the same con-
founding effect of duration of diabetes ob-
served in this study.
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